If you have been reading about GW501516 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
=== NAADP binding proteins === IP3 binds directly to its cognate IP3 receptor which is therefore a true ligand-gated ion channel. In contrast, NAADP does not appear to bind directly to TPCs but requires an intermediate unknown accessory protein(s). In sea urchin egg homogenate and T-cells, the binding protein(s) may be smaller than TPCs themselves, judging by photoaffinity labelling with [32P]azido-NAADP. Therefore, the NAADP receptor was believed to be a multi-protein complex on acidic vesicles. In spite of a decade of graft using conventional biochemical purification, these proteins remained elusive. Recently, two different NAADP-binding proteins have finally been identified that are essential for TPC activation: LSm12 and JPT2.
Opioids by mouth, including both weak opioids such as tramadol and stronger opioids, are also often prescribed. Their appropriateness is uncertain, and opioids are often recommended only when first-line therapies have failed or are contraindicated. This is due to their small benefit and relatively large risk of side effects. The use of tramadol likely does not improve pain or physical function and likely increases the incidence of adverse side effects. Oral steroids are not recommended in the treatment of osteoarthritis. Use of the antibiotic doxycycline orally for treating osteoarthritis is not associated with clinical improvements in function or joint pain and long term use is associated with a high risk of side effects. A 2018 meta-analysis found that oral collagen supplementation for the treatment of osteoarthritis reduces stiffness, but does not improve pain and functional limitation.
The compound accepts or donates the equivalent of H−. Such reactions (summarized in formula below) involve the removal of two hydrogen atoms from a reactant (R), in the form of a hydride ion (H−), and a proton (H+). The proton is released into solution, while the reductant RH2 is oxidized and NAD+ reduced to NADH by transfer of the hydride to the nicotinamide ring.
"Machine Cleans Blood While You Wait"—1950 article on early use of dialysis machine at Bellevue Hospital New York City—an example of how complex and large early dialysis machines were Home Dialysis Museum—History and pictures of dialysis machines through time Introduction to Dialysis Machines—Tutorial describing the main subfunctions of dialysis systems. "First Nations man conducts own dialysis treatments to avoid move to the city"—CBC News (November 30, 2016)
On 3 January 2024, UNICEF chief Catherine M. Russell stated many children in Gaza were facing severe acute malnutrition. On 5 January, UNICEF found 90 percent of children under the age of two were eating two or fewer food groups a day. On 3 February, Hani Mahmoud, an Al Jazeera journalist in Rafah, stated, "We’re seeing children roaming around in Rafah looking for scraps of food." In early January 2024 UNICEF reported that around 90% of children in Gaza under 2 were subjected to severe food poverty, which had jumped from 80% about two weeks prior. Price jumps have also been seen by those attempting to purchase food, with a caregiver purchasing through a procurement company infant formula which had cost him $1,680 before the war, but paying $2,160 in February 2024. The United Nations stated on 10 February 2024 that 10 percent of children under five-years-old were suffering from acute malnourishment. One mother reported feeding her newborn using date paste. On 19 February 2024, UNICEF found that nearly 16 percent of children in northern Gaza under two-years-old were "acutely malnourished", with 3 percent suffering from severe wasting. In early March 2024 UNICEF reported that over 90% of children aged 6–23 months and pregnant or breastfeeding women face severe food poverty with access to two or fewer food groups a day. Child malnutrition is varied throughout Gaza, with northern Gaza experiencing worse food shortages then southern Gaza leading to a child malnutrition rate three times higher according to the WHO.
Sources: en.wikipedia.org
=== Medical insurance coverage === Insurance companies in the United States typically require the physician to provide evidence that a woman's large breasts cause headaches or back and neck pain before they will pay for breast reduction. Insurance companies also mandate a woman who is overweight, which is often the case with gigantomastia, to first lose a certain amount of weight. They also commonly require the patient to try alternative treatments like physical therapy for a year or more.
Hon Lik registered a patent for the modern e-cigarette design in 2003. Hon is credited with developing the first commercially successful electronic cigarette. The e-cigarette was first introduced to the Chinese domestic market in 2004. Many versions made their way to the US, sold mostly over the Internet by small marketing firms. E-cigarettes entered the European market and the US market in 2006 and 2007. The company that Hon worked for, Golden Dragon Holdings, registered an international patent in November 2007. The company changed its name to Ruyan (如烟, literally "like smoke") later the same month, and started exporting its products. Ruyan later changed its company name to Dragonite International Limited. Many e-cigarette makers copied his designs illegally, so Hon didn't receive all of the financial reward for his invention. In 2009 his company successfully sued a competitor in China, and after getting a US patent in 2012, they launched patent infringement lawsuits against multiple US companies. In 2013 his company sold its e-vapor business to Imperial Brands for 75 million USD. As of 2014, most e-cigarettes used a battery-powered heating element rather than the earlier ultrasonic technology design. Initially, their performance did not meet the expectations of users. The e-cigarette continued to evolve from the first-generation three-part device. In 2007, British entrepreneurs Umer and Tariq Sheikh invented the cartomizer. This is a mechanism that integrates the heating coil into the liquid chamber.
These systems can carry more than one type of drug, targeting specific molecules, which helps to deliver a stronger punch to tumor tissues. Altogether, these breakthroughs point to a potential for nanoparticle-based controlled-release therapies in the fields of cancer therapy and personalized medicine.
Klaus Biemann (November 2, 1926 – June 2, 2016) was an Austrian-American professor of chemistry at the Massachusetts Institute of Technology. His work centered on structural analysis in organic and biochemistry. He has been called the "father of organic mass spectrometry" but was particularly noted for his role in advancing protein sequencing with tandem mass spectrometry following pioneering work conducted in this area by Michael Barber.
Sources: en.wikipedia.org
The Food Packet, Long Range Patrol (LRP; pronounced "lurp") was a freeze-dried dehydrated United States military ration used by the Department of Defense. Developed in 1964 and intended for wide adoption during the Vietnam War, its use was eventually limited to American special operations forces during long-range reconnaissance patrols, where bulky canned Meal, Combat, Individual (MCI) rations proved too heavy for extended missions on foot. The LRP had a cold-weather warfare equivalent, the Ration, Cold Weather (RCW). The LRP and RCW were mostly superseded by the Meal, Ready-to-Eat (MRE) in the 1980s. They are no longer produced or used by the U.S. military, having been replaced in 2001 by the Meal, Cold Weather/Food Packet, Long Range Patrol (MCW/LRP), which combines the functions and roles of both rations under a unified system.
== Sources == Meredith, Martin (2010). Mandela: A Biography. New York: PublicAffairs. ISBN 978-1-58648-832-1. Sampson, Anthony (2011) [1999]. Mandela: The Authorised Biography. London: HarperCollins. ISBN 978-0-00-743797-9.
substrate 1. A chemical compound or molecule upon which a particular enzyme directly acts, often but not necessarily binding the molecule by forming one or more chemical bonds. See also ligand. 2. The substance, biotic or abiotic, upon which an organism grows or lives, or by which it is supported; e.g. a particular growth medium used in cell culture. See also substratum.
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.